Superior Outcomes With Continuing Tenofovir Versus Switching to Zidovudine in Second-Line Antiretroviral Therapy in Haiti

We compared viral suppression rates between patients who continued tenofovir disoproxil fumarate (TDF)/lamivudine (3TC) vs switched to zidovudine (ZDV)/3TC in combination with a boosted protease inhibitor after failure of first-line efavirenz/TDF/3TC. We found higher rates of viral suppression with...

Descripción completa

Detalles Bibliográficos
Autores principales: Pierre, Samuel, Bocharova, Iryna, Nguyen, Catherine, Homeus, Fabienne, Julmiste, Gaetane, Macius, Youry, Rouzier, Vanessa, Severe, Patrice, Marcelle Deschamps, Marie, Moise, Colette Guiteau, Bellot, Clovy, Wu, Johnny, Rivera, Vanessa R, Sun, Rochelle, Pape, Jean W, Liautaud, Bernard, Koenig, Serena P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Brief Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8661077/
https://www.ncbi.nlm.nih.gov/pubmed/34901303
http://dx.doi.org/10.1093/ofid/ofab559
_version_ 1784613314830008320
author Pierre, Samuel
Bocharova, Iryna
Nguyen, Catherine
Homeus, Fabienne
Julmiste, Gaetane
Macius, Youry
Rouzier, Vanessa
Severe, Patrice
Marcelle Deschamps, Marie
Moise, Colette Guiteau
Bellot, Clovy
Wu, Johnny
Rivera, Vanessa R
Sun, Rochelle
Pape, Jean W
Liautaud, Bernard
Koenig, Serena P
author_facet Pierre, Samuel
Bocharova, Iryna
Nguyen, Catherine
Homeus, Fabienne
Julmiste, Gaetane
Macius, Youry
Rouzier, Vanessa
Severe, Patrice
Marcelle Deschamps, Marie
Moise, Colette Guiteau
Bellot, Clovy
Wu, Johnny
Rivera, Vanessa R
Sun, Rochelle
Pape, Jean W
Liautaud, Bernard
Koenig, Serena P
author_sort Pierre, Samuel
collection PubMed
description We compared viral suppression rates between patients who continued tenofovir disoproxil fumarate (TDF)/lamivudine (3TC) vs switched to zidovudine (ZDV)/3TC in combination with a boosted protease inhibitor after failure of first-line efavirenz/TDF/3TC. We found higher rates of viral suppression with continued TDF/3TC compared with switching to ZDV/3TC.
format Online
Article
Text
id pubmed-8661077
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-86610772021-12-10 Superior Outcomes With Continuing Tenofovir Versus Switching to Zidovudine in Second-Line Antiretroviral Therapy in Haiti Pierre, Samuel Bocharova, Iryna Nguyen, Catherine Homeus, Fabienne Julmiste, Gaetane Macius, Youry Rouzier, Vanessa Severe, Patrice Marcelle Deschamps, Marie Moise, Colette Guiteau Bellot, Clovy Wu, Johnny Rivera, Vanessa R Sun, Rochelle Pape, Jean W Liautaud, Bernard Koenig, Serena P Open Forum Infect Dis Brief Reports We compared viral suppression rates between patients who continued tenofovir disoproxil fumarate (TDF)/lamivudine (3TC) vs switched to zidovudine (ZDV)/3TC in combination with a boosted protease inhibitor after failure of first-line efavirenz/TDF/3TC. We found higher rates of viral suppression with continued TDF/3TC compared with switching to ZDV/3TC. Oxford University Press 2021-11-23 /pmc/articles/PMC8661077/ /pubmed/34901303 http://dx.doi.org/10.1093/ofid/ofab559 Text en © The Author(s) 2021. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Brief Reports
Pierre, Samuel
Bocharova, Iryna
Nguyen, Catherine
Homeus, Fabienne
Julmiste, Gaetane
Macius, Youry
Rouzier, Vanessa
Severe, Patrice
Marcelle Deschamps, Marie
Moise, Colette Guiteau
Bellot, Clovy
Wu, Johnny
Rivera, Vanessa R
Sun, Rochelle
Pape, Jean W
Liautaud, Bernard
Koenig, Serena P
Superior Outcomes With Continuing Tenofovir Versus Switching to Zidovudine in Second-Line Antiretroviral Therapy in Haiti
title Superior Outcomes With Continuing Tenofovir Versus Switching to Zidovudine in Second-Line Antiretroviral Therapy in Haiti
title_full Superior Outcomes With Continuing Tenofovir Versus Switching to Zidovudine in Second-Line Antiretroviral Therapy in Haiti
title_fullStr Superior Outcomes With Continuing Tenofovir Versus Switching to Zidovudine in Second-Line Antiretroviral Therapy in Haiti
title_full_unstemmed Superior Outcomes With Continuing Tenofovir Versus Switching to Zidovudine in Second-Line Antiretroviral Therapy in Haiti
title_short Superior Outcomes With Continuing Tenofovir Versus Switching to Zidovudine in Second-Line Antiretroviral Therapy in Haiti
title_sort superior outcomes with continuing tenofovir versus switching to zidovudine in second-line antiretroviral therapy in haiti
topic Brief Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8661077/
https://www.ncbi.nlm.nih.gov/pubmed/34901303
http://dx.doi.org/10.1093/ofid/ofab559
work_keys_str_mv AT pierresamuel superioroutcomeswithcontinuingtenofovirversusswitchingtozidovudineinsecondlineantiretroviraltherapyinhaiti
AT bocharovairyna superioroutcomeswithcontinuingtenofovirversusswitchingtozidovudineinsecondlineantiretroviraltherapyinhaiti
AT nguyencatherine superioroutcomeswithcontinuingtenofovirversusswitchingtozidovudineinsecondlineantiretroviraltherapyinhaiti
AT homeusfabienne superioroutcomeswithcontinuingtenofovirversusswitchingtozidovudineinsecondlineantiretroviraltherapyinhaiti
AT julmistegaetane superioroutcomeswithcontinuingtenofovirversusswitchingtozidovudineinsecondlineantiretroviraltherapyinhaiti
AT maciusyoury superioroutcomeswithcontinuingtenofovirversusswitchingtozidovudineinsecondlineantiretroviraltherapyinhaiti
AT rouziervanessa superioroutcomeswithcontinuingtenofovirversusswitchingtozidovudineinsecondlineantiretroviraltherapyinhaiti
AT severepatrice superioroutcomeswithcontinuingtenofovirversusswitchingtozidovudineinsecondlineantiretroviraltherapyinhaiti
AT marcelledeschampsmarie superioroutcomeswithcontinuingtenofovirversusswitchingtozidovudineinsecondlineantiretroviraltherapyinhaiti
AT moisecoletteguiteau superioroutcomeswithcontinuingtenofovirversusswitchingtozidovudineinsecondlineantiretroviraltherapyinhaiti
AT bellotclovy superioroutcomeswithcontinuingtenofovirversusswitchingtozidovudineinsecondlineantiretroviraltherapyinhaiti
AT wujohnny superioroutcomeswithcontinuingtenofovirversusswitchingtozidovudineinsecondlineantiretroviraltherapyinhaiti
AT riveravanessar superioroutcomeswithcontinuingtenofovirversusswitchingtozidovudineinsecondlineantiretroviraltherapyinhaiti
AT sunrochelle superioroutcomeswithcontinuingtenofovirversusswitchingtozidovudineinsecondlineantiretroviraltherapyinhaiti
AT papejeanw superioroutcomeswithcontinuingtenofovirversusswitchingtozidovudineinsecondlineantiretroviraltherapyinhaiti
AT liautaudbernard superioroutcomeswithcontinuingtenofovirversusswitchingtozidovudineinsecondlineantiretroviraltherapyinhaiti
AT koenigserenap superioroutcomeswithcontinuingtenofovirversusswitchingtozidovudineinsecondlineantiretroviraltherapyinhaiti

Ejemplares similares